Salusin-α attenuates inflammatory responses in vascular endothelial cells


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Atherosclerosis accounts for numerous cardiovascular diseases, and cytokines have a critical role in acceleration or suppression of disease. Salusin-α presents a new class of bioactive peptides that can have anti-atherogenic properties. Therefore, the effects of salusin-α on the expression of some pro- and anti-inflammatory cytokines and on TNF-α-induced inflammatory responses in human umbilical vein endothelial cells (HUVECs) were examined. The involvement of the NF-κB pathway in effects of salusin-α in HUVECs was checked using Bay 11-7082 as an NF-κB inhibitor. The mRNA expression of pro-inflammatory cytokines including IL-6, IL-8, and IL-18 and anti-inflammatory cytokine IL-1Ra was assessed by real-time PCR. The protein levels of cytokines were measured by the ELISA method. Salusin-α suppressed both mRNA and protein expression of pro-inflammatory cytokines and induced mRNA and protein expression of IL-1Ra in HUVECs. Salusin-α suppressed TNF-α-induced inflammatory responses in HUVECs. The down-regulatory or up-regulatory effects of salusin-α on expression of cytokines could not be influenced by Bay 11-7082 pretreatment. Our findings indicate anti-inflammatory effects of salusin-α and suggest a novel peptide-based therapeutic strategy for atherosclerosis.

Sobre autores

Maryam Esfahani

Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences and Isfahan Pharmaceutical Sciences Research Center

Email: najafi2535@gmail.com
Irã, Isfahan

Masoud Saidijam

Research Center for Molecular Medicine

Email: najafi2535@gmail.com
Irã, Hamadan

Mohammad Goodarzi

Research Center for Molecular Medicine; Hamadan University of Medical Sciences, School of Medicine

Email: najafi2535@gmail.com
Irã, Hamadan; Hamadan

Ahmad Movahedian

Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences and Isfahan Pharmaceutical Sciences Research Center

Autor responsável pela correspondência
Email: Movahedian@pharm.mui.ac.ir
Irã, Isfahan

Rezvan Najafi

Research Center for Molecular Medicine

Autor responsável pela correspondência
Email: najafi2535@gmail.com
Irã, Hamadan


Declaração de direitos autorais © Pleiades Publishing, Ltd., 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies